12:00 AM
 | 
Aug 10, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vidaza azacitidine regulatory update

The National Comprehensive Cancer Network (NCCN) updated its clinical practice guidelines in oncology to recommend Celgene's Vidaza azacitidine as the preferred treatment for patients with intermediate-2 and high-risk myelodysplastic syndromes (MDS)....

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >